Building a future together

Seamlessly visualize quality intellectual capital without superior collaboration and base portals.

Together we can envision, inspire
and transform your business

Our Business Consulting Services are structured to address a company’s end-to-end business needs.

Business Strategy

We’ll help you understand your business and customer insights while developing a compelling vision, strategy and overall blueprint for driving competitive advantage.

People and Change

Whether your company is undergoing a significant transformation or you need to strengthen your culture, we’ll help your leaders equip your people and culture to thrive.

Enterprise Management

From portfolio management to project delivery, we will work with you to deliver strategies and initiatives in an agile, rapid and value-driven manner, up to modern standards.

Navigating business
challenges, together

We can guide you to a Business Anywhere future, one where every interaction is smart and seamless, every process is fully automated and paperless, and everyone is ready for whatever the future holds.
  • Commit to Delivery Excelence
  • Embrace Integrity And Openess
  • Practice Responsible Stewardship
  • Invest In An Exceptional Culture
  • Strive To Innovate

We’ve always done things
a little differently here

We’ve grown our business on a set of three building blocks: enjoy the people you work with, have fun, and do great work.

Head Of TeamEvelynn Bradford

Seamlessly empower fully researched growth strategies and interoperable internal or organic sources for development.

HR ConsultantJennie Holmwood

Interactively productize premium technologies whereas interdependent quality vectors and enterprise experiences via global markets.

Business ConsultantOwen Lee

Coordinate proactive e-commerce via process-centric outside the box thinking, completely pursue scalable customer service through potentialities.

Marketing ConsultantDennis Anderson

Uniquely enable accurate supply chains rather than frictionless technology, network focused materials and manufactured products

We'll help you gain a new perspective!

Competently parallel task fully researched data and enterprise process improvements. Collaboratively expedite quality manufactured products via client-focused results.

Delivering positive change


    Great client stories
    We have worked together on projects and I was always impressed with their innovative approach to any situation.
    Jason Williams
    Williams & Son LLC
    Ad Astra brings tremendous value to my company. We have generated more leads in the last 45 days than in the last 2 years.
    Takashi Nakagawa
    Lease & Plan Experts
    Ad Astra’s team consulting proved to be the tune up we needed to improve our campaign results, and it really shows on our turnover.
    Brenda McIntyre
    Majestic Vista LLC
    Business consulting
    We transform your business from the people to the processes.
    Instant solutions
    We plan, build and deliver technology to solve problems.
    Always succeed
    We define your digital strategy and make marketing work.

    Your catalyst for empowerment

    Uniquely enable accurate supply chains rather than frictionless technology. Globally network focused materials vis-a-vis cost effective manufactured products.

    Define & Structure

    Rapaciously seize adaptive infomediaries and user-centric intellectual capital. Collaboratively unleash market-driven "outside the box" thinking for long-term high-impact solutions. Enthusiastically engage fully tested process improvements before top-line platforms.

    Analysis & Plan

    Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Organically grow the holistic world view of disruptive innovation.

    Solutions & Findings

    Completely synergize resource taxing relationships via premier niche markets. Professionally cultivate one-to-one customer service with robust ideas. Dynamically innovate resource-leveling customer service for state of the art customer service.

    Develop Recommendations

    Proactively envisioned multimedia based expertise and cross-media growth strategies. Seamlessly visualize quality intellectual capital without superior collaboration and idea-sharing. Holistically pontificate installed base portals after maintainable products.

    Enjoy the people you work with

    We believe consulting is a team sport, which is why we don’t just work for you – but with you to uncover new ideas that optimize processes, elevate technology, and help you compete in a digital world.

    Our clients and employees deserve an unmatched experience. That’s why we’re here – to provide experiences like no other. Learn more about the values that define us, motivate us, and guide our actions.

    We didn’t start in a conference room. Instead, we started on a couch. And we’ve grown our business on a set of three building blocks. Enjoy the people you work with, have fun, and do great work yourself.




    News & Articles

    While our leaders represent a vast array of expertise and perspectives, all are committed to doing what’s best for our clients and our people in a way that is unmatched by other firms.
    5 Must-Know Insights into the Biopharmaceutical Manufacturing Market
    The Biopharmaceutical Market Worldwide Will Be Worth Nearly One Trillion USD by 2030 The Global Biopharmaceutical Market is anticipated to be valued at almost $1 trillion USD by 2030 (As stated by Statista 2023). As chronic diseases like cancer, diabetes, and heart disease are becoming more prevalent around the world, there is a surge in...
    March 1, 2023
    5 Biggest Challenges for the Market Research Pharmaceutical Industry In 2023
    The biopharma industry has witnessed extensive growth in recent years due to the rising demand for drugs to treat and cure a wide range of diseases. The biopharma industry is changing how we identify and treat diseases thanks to developments in gene editing, biosensors, and other technologies. However, with this growth comes a plethora of...
    February 28, 2023
    Real-Time Data, Development, and Analysis of Pharmaceutical Market Data
    IMAPAC has a new comprehensive market intelligence tool to produce pharma and pharmaceutical market data in real-time. The visualization tool makes it possible to analyze historical and current data in real time in a matter of seconds instead of many hours. Apart from scalability, the data tool opens a spectrum of new analytical and reporting...
    February 28, 2023
    Understanding Market Research in Pharmaceutical Industry : An Overview
    With the increasing complexity of products, competition, regulations, and global markets, the need for comprehensive market intelligence has become increasingly essential in order to remain successful in the most rapidly expanding industry- Biopharmaceuticals. For biopharma companies, market research services are proving to be a valuable asset in product development. Companies conduct market research in pharmaceutical...
    February 27, 2023
    Medigen applies for Australian vaccine approval
    Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine. Article Summary Medigen Vaccine Biologics Corp applied to Australian medicines regulator for provisional approval of the COVID-19 vaccine and has delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say...
    July 6, 2022
    Prestige Biopharma announces International Non-proprietary Name for PBP1510
    Excerpt Prestige Biopharma Limited, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO). Article Summary Prestige Biopharma Limited first-in-class antibody has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’. INN-Ulenistamab, which is also known as...
    July 6, 2022
    WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes
    Excerpt WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. Article Summary Wuxi Biologics, a global CRDMO service company, recently opened its DP5 facility in Wuxi, China. The facility is the ninth active facility in WuXi Biologics’ global network.   A continuous and steady isolator filling system...
    July 6, 2022
    Astellas Announces the Opening of Its New Gene Therapy Manufacturing Facility in North Carolina
    Astellas Pharma Inc has announced the opening of a new late stage clinical and commercial manufacturing facility in Sanford, North Carolina, US. The facility will allow the company to expand its resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope. Article Summary The new 135,000 square-foot state-of-the-art...
    July 6, 2022
    Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World
    The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs has accelerated the plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer. Article Summary Planning has begun on a massive...
    July 6, 2022
    Prescient Therapeutics Unveils its New Cell Therapy Platform – CellPryme-M
    A clinical-stage oncology company Prescient Therapeutics (PTX) has launched its second cell therapy platform, CellPryme-M, which produces superior cells with greater cancer killing activity. This platform opens commercial opportunities for the company to incorporate it into third-party manufacturing processes. Article Summary PTX has developed this new platform technology in association with its research partner, Peter...
    July 6, 2022
    Tessa Therapeutics Closes a US$126 million Series A financing Round
    Article Summary Tessa Therapeutics Ltd has announced the close of a US$126 million Series A financing round. The funding was led by Polaris Partners and existing investors, including Temasek, EDBI, Heliconia Capital and Heritas Capital. In conjunction with the financing, Amy Schulman and Darren Carroll, Managing Partners at Polaris Partners, have joined Tessa’s Board of...
    July 6, 2022
    The European Investment Bank (EIB) has provided €75 million to the Institut Pasteur de Dakar for the construction of a new vaccine manufacturing facility.
    Excerpt Large-scale funding for the Institut Pasteur de Dakar’s new vaccine manufacturing facility, a leader in the area in Africa. The facility, which would produce up to 300 million doses per year against COVID-19 and other endemic diseases, is projected to considerably reduce Africa’s reliance on imported vaccines and support equal access to medicines. This...
    July 6, 2022
    GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
    Excerpt GSK will pay $2.1 billion up front and up to $1.2 billion in development milestone payments. The proposed acquisition will give the company access to a next-generation 24-valent pneumococcal vaccine candidate in phase II development as well as MAPSTM technology, which is extremely innovative. Encourages the development of a diverse portfolio of novel vaccines...
    July 6, 2022
    World Bank Support for Country Access to COVID-19 Vaccines
    Excerpt The World Bank has approved $9.5 billion in operations to assist vaccination rollout in 77 countries as of June 15, 2022. Article Summary The World Bank Group is collaborating with partners on the world’s largest vaccine programme to combat the COVID-19 pandemic. The World Bank’s Board of Executive Directors adopted a $6 billion Global...
    July 6, 2022
    Nippon Express Launches Ultra-low Temperature-controlled Logistics Service for Pharmaceutical Industry
    Excerpt: Nippon Express Co., Ltd. (hereinafter “Nippon Express”), a group company of Nippon Express Holdings, Inc., launched on May 30 a logistics service capable of handling goods requiring ultra-low temperatures (-20 C to -85 C) for the pharmaceutical industry.   Article Summary: As a priority approach for the core business growth strategy outlined in the...
    July 6, 2022
    Samsung Biologics to build first overseas factory in US
    Excerpt: Samsung Biologics CEO John Rim said Monday the US states of California, North Carolina, Washington and Texas are the strongest candidates the South Korean contract manufacturing organization is considering for its first overseas production facility.   Article Summary: Pointing out that some of the US’ major bio clusters are located in those four states,...
    July 6, 2022
    GXO Logistics to open warehouse for pharmaceutical sector
    Excerpt: Logistics provider GXO plans to open a 20,000m2  warehouse dedicated to the pharmaceutical sector in Caleppio di Settala in Milan, Italy, by the end of June 2022. Article Summary: The location was chosen for its proximity to major surface transportation arteries to help enable pharmaceutical companies to meet the stringent lead times required for...
    July 6, 2022
    US drug supply chain alternative to China might run through Canada, Latin America
    Excerpt: Centre for Strategic and International Studies panellists from Canada, Mexico, Brazil and Colombia discuss speeding pharmaceutical production and trade with US About 80 per cent of all fine chemicals come from China, according to one estimate, leading to a medical supply chain vulnerability   Article Summary: Representatives of Canada and three Latin American nations...
    July 6, 2022
    Pfizer and Valneva enter into an equity subscription agreement and update the terms of the collaboration agreement for Lyme disease vaccine candidate VLA15.
    Excerpt Pfizer will invest €90.5 million in Valneva Planned Phase 3 study confirmed to initiate in Q3 2022   Article Summary Valneva announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As part of the Equity Subscription...
    July 6, 2022
    ABVC Biopharma Submit Phase II Study to the HREC
    Excerpt ABVC Biopharma, Inc. a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the submission of its Vitrargus Phase II study to the Australian Bellberry Human Research Ethics Committee (HREC). Article Summary If the submission is received, HREC approval will lead to a Clinical Trial Notification (CTN) submission to...
    July 6, 2022
    BioCina COVID-19 Vaccine to be Manufactured in Adelaide as the Company Expands CDMO Service
    Excerpt The new BioCina vaccine is being manufactured in an Adelaide facility purchased by the Bridgewest group in 2020 from Pfizer, maker of a successful Covid-19 vaccine – though Pfizer’s vaccine targets only the original strain of the disease. Article Summary The vaccine is claimed to be easily adapted to new variants of Covid-19, making...
    July 6, 2022
    Impressive Trial Results for Propanc Biopharma with Novel Cancer Treatment
    Excerpt Victoria’s Propanc Biopharma Inc. , a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the results from a small trial of just 18 rectal cancer patients in complete remission using an immunotherapy called dostarlimab are “impressive,” whilst acknowledging there’s more work to be done.  Article Summary...
    July 6, 2022
    Medigen Seeks Therapeutic Goods Administration (TGA) Approval for COVID-19 Vaccine
    Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine, the pharmaceutical company said in a filing with the Taipei Exchange yesterday. Article Summary The company yesterday delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say when the regulator...
    July 6, 2022

    Don't need to look very far to get a better perspective on your business!